AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 11.5 |
Market Cap | 843.83M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.61 |
PE Ratio (ttm) | -9.91 |
Forward PE | n/a |
Analyst | Buy |
Ask | 17.2 |
Volume | 608,508 |
Avg. Volume (20D) | 357,172 |
Open | 15.24 |
Previous Close | 15.10 |
Day's Range | 15.11 - 16.57 |
52-Week Range | 12.17 - 29.60 |
Beta | undefined |
About TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondro...
Analyst Forecast
According to 6 analyst ratings, the average rating for TYRA stock is "Buy." The 12-month stock price forecast is $30.5, which is an increase of 91.10% from the latest price.
2 months ago · seekingalpha.com
Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection PointTyra Biosciences will release interim data for its FGFR3-inhibitor TYRA-300 in treating urothelial carcinoma and solid tumors at ENA 2024 on October 25th. Positive interim data could advance TYRA-300 ...